Back to search

Switzerland· 65643003

Uptravi 400 mcg, Filmtabletten

A selexipag product containing selexipagum, registered in Switzerland by Janssen-Cilag AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC B01AC27

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedUptravi 400 mcg, FilmtablettenATCB01AC27REGISTER NO.65643003PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Selexipag is registered in 13 of 19 countries.

Countries holding a registration under ATC B01AC27 (selexipag), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Selexipag · ATC B01AC27

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of selexipag costs, country by country.

Normalised to the WHO defined daily dose (1.8 mg), the median price runs from $809.99 in Switzerland to $1232.99 in Italy — a ×1.5 gap.

  • Switzerland: $809.99 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Selexipag · price per daily dose (1.8 mg)

USD · FX 28 Sept 2026

  • IT Italy$1232.99
  • CH Switzerland$809.99
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
selexipagum
Manufacturer
Janssen-Cilag AG
Country
Switzerland (CH)
ATC code
B01AC27
ATC class
Selexipag
Defined daily dose
1.8 mg, O
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680656430036
    60 Stk
    CHF 4854.3

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

237 interactions on record for selexipag.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Selexipag · interactions on record

237 records

  • 1 severe
  • 232 moderate
  • 4 minor

Most severe, free to view

  • GemfibrozilC10AB04severe
  • PapaverineA03AD01moderate
  • MannitolA06AD16moderate
  • GlycerolA06AX01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Selexipag in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All selexipag products

Authorised across Europe · EMA

The same active substance is authorised in 19 EEA countries. Names it is sold under:

  • Austria · Selexipag Ratiopharm
  • Cyprus · Selexipag Accord
  • Denmark · Selexipag Accord, Selexipag Stada
  • Estonia · Selexipag Stada
  • Spain · Selexipag Accord, Selexipag Stada
  • Greece · Xipeno
  • Croatia · Seleksipag Accord
  • Ireland · Selexipag Accord, Selexipag Clonmel
  • Iceland · Selexipag Stada, Uptravi
  • Italy · Selexipag Accord, Selexipag Eg
  • Liechtenstein · Uptravi
  • Lithuania · Selexipag Stada
  • Latvia · Selexipag Stada
  • Malta · Selexipag Clonmel
  • Netherlands · Seleksipag Accord, Selexipag Abdi
  • Norway · Selexipag Accord, Selexipag Stada
  • Poland · Selexipag, Selexipag Accord
  • Portugal · Selexipag Accord, Selexipag Teva
  • Sweden · Selexipag, Selexipag Accord

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fc7b19f9-6dc7-4472-b55c-e2dc39de872e
GET /v1/drugs/fc7b19f9-6dc7-4472-b55c-e2dc39de872e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "selexipagum 0.4 mg",
  "valid_from": "2016-11-01",
  "limitations": "[{\"description\":\"Pulmonale Hypertonie bei Patienten mit NYHA III und IV (Einteilung nach New York Heart Association).\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2016-11-01\"}]",
  "galenic_form": "Filmtabl 400 mcg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2016-11-01",
  "self_retention_pct": 10
}

See everything about selexipag.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.